Global pharmaceutical industry has become the field for serious patent-related battles between producers of original drugs and manufacturers of generics.
Particularly this trend is widely observed in EAEU and CIS, where the regulatory bodies and courts have not yet developed an efficient mechanism for maintaining the balance of interests between the pharmaceutical businesses, state and patients.
Having vast expertise in providing legal protection to large Russian and international pharmaceuticals and healthcare companies in EAEU and CIS, Lidings publishes Legal Digest highlighting the most notable patents disputes in Life Sciences that have been recently taking place in those jurisdictions.